Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31730995 | 1.00 | GPR119 (0.44) | GPR119USP30NLRP3TRPV1STS | |
| SCHEMBL31096032 | 1.00 | GPR119 (0.44) | GPR119USP30NLRP3TRPV1STS | |
| SCHEMBL31200561 | 0.88 | SMN1; SMN2 (0.40) | GPR119USP30STS | |
| SCHEMBL31200541 | 0.86 | GPR119 (0.41) | GPR119USP30 | |
| SCHEMBL31200755 | 0.85 | JAK3 (0.44) | NLRP3TRPV1 | |
| SCHEMBL29270328 | 0.85 | NLRP3 (0.44) | NLRP3TRPV1 | |
| SCHEMBL25417272 | 0.83 | GPR119 (0.46) | GPR119USP30 | |
| SCHEMBL31200661 | 0.83 | GPR119 (0.46) | GPR119USP30 | |
| SCHEMBL25420799 | 0.81 | GPR119 (0.44) | GPR119USP30TRPV1STS | |
| SCHEMBL31200700 | 0.81 | GPR119 (0.44) | GPR119USP30TRPV1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680601-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | Sanofi (FR) | 2026-01-21 | — | — | EP | disclosed |
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-10-31 | — | — | US | disclosed |
| WO-2024188994-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | NLRP3, NOD1, NLRP1 | GPR119 343/4885USP30 3707/4885NLRP3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.